In a nutshell This study aimed to compare enasidenib (Idhifa) to current standard of care therapies for patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and an isocitrate dehydrogenase 2 (IDH2) mutation who are ineligible for hematopoietic stem cell transplantation (HSCT). This study concluded that enasidenib significantly...
Read More
In a nutshell This study compared the outcomes between radical prostatectomy (RP; prostate-removal surgery) and different types of radiotherapy (RT) in older patients with localized prostate cancer (PCa). The study found that RT offers similar cancer-specific outcomes to RP for low- to intermediate-risk patients. Some background...
Read More
In a nutshell This study compared the effectiveness and safety of S-1 (tegafur/gimeracil/oteracil) and oxaliplatin (Eloxatin) combined with bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with previously untreated advanced colorectal cancer with wild-type KRAS. This study concluded that the safety and effectiveness of...
Read More
In a nutshell This study looked at the use of sacral neuromodulation (SNM) with the InterStim device in patients with overactive bladder (OAB). It found that SNM improved the symptoms of OAB over 3 years. Some background OAB is a condition in which the bladder contracts involuntarily leading to a sudden, urgent need to urinate....
Read More
In a nutshell This study looked at the use of electrical stimulation (ES) for the treatment of stress urinary incontinence (SUI) in women. It found that ES improved incontinence-related quality of life over in the short-term. Some background SUI is a condition in which urine leaks out involuntarily when increased pressure is...
Read More
In a nutshell This study described the real-world effectiveness and safety of arsenic trioxide (ATO; Trisenox) combined with all-trans retinoic acid (ATRA; Vesanoid), without chemotherapy, in patients with newly diagnosed acute promyelocytic leukemia (APL). The authors concluded that a combination of ATO and ATRA showed good results for the...
Read More
In a nutshell This study evaluated the effectiveness and safety of a venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Decadron combination with or without bortezomib (Velcade) in patients with relapsed or refractory (RR) multiple myeloma (MM). The authors concluded that these treatment combinations produced high...
Read More
In a nutshell The study aimed to investigate whether reduced-intensity conditioning (RIC) hemopoietic stem cell transplantation (HSCT) improves the outcomes of patients with chronic lymphocytic leukemia (CLL) with and without Richter's transformation (RT). This study concluded that this treatment may be suitable in early...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of venetoclax (Venclexta) combined with intensive chemotherapy in patients aged 65 or younger with acute myeloid leukemia (AML). This study concluded that venetoclax added to intensive chemotherapy was safe and effective in these...
Read More
In a nutshell This study compared two treatment regimes for HER2 positive breast cancer; pyrotinib (Irene) plus vinorelbine (Navelbine), or lapatinib (Tykerb) plus capecitabine (Xeloda). It found that pyrotinib plus vinorelbine (PV) improved survival without cancer progressing compared to lapatinib plus capecitabine (LC). Some background...
Read More
In a nutshell This study evaluated the best approach for treating lateral lymph node (LLNs) metastasis in patients with locally advanced rectal cancer (LARC). The data showed that a radiation dose boost is an effective way of increasing the response rate and decreasing recurrence rates in these patients. Some background Rectal cancer (RC) is one...
Read More
In a nutshell This study described real-world outcomes for patients with chronic myeloid leukemia (CML) that started a second-generation tyrosine kinase inhibitor (TKI) therapy and needed to switch to an alternative TKI. The authors concluded that intolerance was the major reason to switch to an alternative TKI and that outcomes were very good...
Read More
